Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Drechsler, C; Delgado, G; Wanner, C; Blouin, K; Pilz, S; Tomaschitz, A; Kleber, ME; Dressel, A; Willmes, C; Krane, V; Krämer, BK; März, W; Ritz, E; van Gilst, WH; van der Harst, P; de Boer, RA.
Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies.
J Am Soc Nephrol. 2015; 26(9):2213-2221
Doi: 10.1681/ASN.2014010093
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- März Winfried
- Pilz Stefan
- Tomaschitz Andreas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Galectin-3 has been linked to incident renal disease, experimental renal fibrosis, and nephropathy. However, the association among galectin-3, renal function, and adverse outcomes has not been described. We studied this association in two large cohorts of patients over a broad range of renal function. We measured galectin-3 concentrations in baseline samples from the German Diabetes mellitus Dialysis (4D) study (1168 dialysis patients with type 2 diabetes mellitus) and the Ludwigshafen Risk and Cardiovascular Health (LURIC) study (2579 patients with coronary angiograms). Patients were stratified into three groups: eGFR of ≥90 ml/min per 1.73 m(2), 60-89 ml/min per 1.73 m(2), and <60 ml/min per 1.73 m(2). We correlated galectin-3 concentrations with demographic, clinical, and biochemical parameters. The association of galectin-3 with clinical end points was assessed by Cox proportional hazards regression within 10 years (LURIC) or 4 years (4D) of follow-up. Mean±SD galectin-3 concentrations were 12.8±4.0 ng/ml (eGFR≥90 ml/min per 1.73 m(2)), 15.6±5.4 ng/ml (eGFR 60-89 ml/min per 1.73 m(2)), 23.1±9.9 ng/ml (eGFR<60 ml/min per 1.73 m(2)), and 54.1±19.6 ng/ml (dialysis patients of the 4D study). Galectin-3 concentration was significantly associated with clinical end points in participants with impaired kidney function, but not in participants with normal kidney function. Per SD increase in log-transformed galectin-3 concentration, the risks of all-cause mortality, cardiovascular mortality, and fatal infection increased significantly. In dialysis patients, galectin-3 was associated with the combined end point of cardiovascular events. In conclusion, galectin-3 concentrations increased with progressive renal impairment and independently associated with cardiovascular end points, infections, and all-cause death in patients with impaired renal function. Copyright © 2015 by the American Society of Nephrology.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Cardiovascular Diseases - mortality
- Cause of Death -
- Diabetic Nephropathies - blood
- Diabetic Nephropathies - mortality
- Diabetic Nephropathies - therapy
- Female -
- Follow-Up Studies -
- Galectin 3 - blood
- Galectin 3 - epidemiology
- Glomerular Filtration Rate -
- Humans -
- Infection - mortality
- Male -
- Middle Aged -
- Renal Dialysis -
- Renal Insufficiency, Chronic - blood
- Renal Insufficiency, Chronic - mortality
- Renal Insufficiency, Chronic - therapy
- Severity of Illness Index -